[ad_1]
Transverse myelitis was diagnosed in one of the participants in the clinical trials of the experimental AstraZeneca vaccine, according to information from the New York Times, as a result of which the tests were “frozen” until it was determined whether or not it was a side effect of the vaccine. It is an inflammatory syndrome of the spinal cord that is often caused by viral infections.
According to Stat News, the patient is expected to recover.
AstraZeneca today announced the cessation of clinical trials, including end-stage trials, to allow an independent scientific committee to assess safety conditions after one of the participants in a noncommunicable disease has become infected.
According to the BBC, the MHRA medical regulatory authority will make the final decision on resuming clinical trials within a few days.
“This is a routine procedure followed when potentially unexplained illness occurs in one of the tests,” AstraZeneca said in a statement.
50,000 volunteers worldwide in clinical trials
The AZD1222 experimental vaccine is in the final stages of clinical trials in the United States, Brazil, and South Africa, with additional trials scheduled in Japan and Russia.
The tests will have a total of 50,000 participants around the world.
South Korea has said it will consider closing the trials and reviewing its plan to participate in vaccine production.
However, a spokesman for the South Korean Ministry of Health said that “it is not uncommon for clinical trials to stop when there is an interaction of factors.”
The U.S. National Institutes of Health, which funds AstraZeneca’s testing program, declined to comment on the development.
The American company Moderna, one of the pioneers in the vaccine race, announced that there is no impact on its own vaccine study for Covid-19.
Historical commitment
Nine major European and US pharmaceutical companies have committed to meeting safety and efficacy requirements in the development of their experimental vaccines, despite the urgent need to address the pandemic.
The companies, which include AstraZeneca, Moderna and Pfizer, issued a “landmark commitment” following concerns about safety cuts due to strong political pressure to develop a vaccine for COVID-19.
The other companies signing the engagement announcement are Johnson & Johnson, Merck & Co, GlaxoSmithKline, Novavax Inc, Sanofi and BioNTech.
AstraZeneca share drop
Following the announcement of the discontinuation of clinical trials, AstraZeneca’s share of the London Stock Exchange fell 2% and the share of AstraZeneca Pharma India Ltd.’s Indian subsidiary fell 12%.
Source: skai.gr, ΑΠΕ-ΜΠΕ,
